Product
Investigational Arm - Secukinumab
1 clinical trial
2 indications
Indication
PsoriasisIndication
Non-alcoholic Fatty Liver DiseaseClinical trial
A Randomized, Double-blind, Multicenter, 24-week Study of Subcutaneous Secukinumab to Assess Anti-interleukin-17A Treatment in Plaque Psoriasis Patients With Coexisting Non-alcoholic Fatty Liver Disease (pINPOINt)Status: Terminated, Estimated PCD: 2021-06-29